biostudies-literatureUnknown16Rosso-Fernandez C<h4>Background</h4>Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.<h4>Methods/design</h4>The MagicBullet clinical trial is an investigator-driven clinical study, funded by the Seventh Framework Program of the European Commission. This is designed as a phase IV, randomized, controlled, open label, non-inferiority and international trial to assess the safety and efficacy of colistin versus meropeneTrials102https://www.ebi.ac.uk/biostudies/studies/S-EPMC4374401biostudies-literatureSafety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.PMC4374401Pulido MPachon MEGeorgopoulos DFernandez CRArmaganidis AMonteau SGallego JMDe Blasi RPneumatikos LOrtega ACKoutsoukou ABaltopoulos GAlvarez-Rocha LKomnos AGutierrez ADiaz-Miguel ROGonzalez JCPennisi MZakynthinos EBonastre JRoca RFRanieri VMCrespo RZMartinez JRosso-Fernandez CMilara CAntonelli MNakos Gde Rosa FGarnacho-Montero JCamerino RSMartinez FPde los Santos MPGarcia MSMagicBullet study groupLopez CCisneros JMPerez FCortes PVMontero JGCubiles LGMcConnell MDe Gasperi AGutierrez MHde la Torre Prados MVRocco MGallmore PRDe Robertis-Rosalba EDimopoulos GMoreno PfalseSafety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.<h4>Background</h4>Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.<h4>Methods/design</h4>The MagicBullet clinical trial is an investigator-driven clinical study, funded by the Seventh Framework Program of the European Commission. This is designed as a phase IV, randomized, controlled, open label, non-inferiority and international trial to assess the safety and efficacy of colistin versus meropene2015-01-01T00:00:00Z2015 Mar2025-04-18T19:49:49.341Z2019-03-27T01:48:48ZS-EPMC43744012587279010.1186/s13063-015-0614-4